NCT07588152 Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
| NCT ID | NCT07588152 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Indiana University |
| Condition | Glaucoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-06-05 |
| Primary Completion | 2028-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 50 participants in total. It began in 2026-06-05 with a primary completion date of 2028-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of ocular hypertension or open-angle glaucoma * Eye examination within the past year * For glaucoma subjects: structural (optic nerve and/or retinal nerve fiber layer) and functional (visual field) findings consistent with glaucoma * Best-corrected visual acuity of 20/100 or better * Open anterior chamber angle as confirmed by gonioscopy and anterior segment optical coherence tomography (AS-OCT) * Intraocular pressure between 18 and 34 mmHg (treatment-naïve or after washout, if applicable) Exclusion Criteria: * Known intolerance to netarsudil ophthalmic solution * Corneal scarring or active corneal disease that would interfere with imaging * Inability to tolerate gonioscopy procedures * Females of childbearing potential who are not using effective contraception or are not sterile * Any condition that, in the opinion of the investigator, would place the subject at increased risk or interfere with study completion
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07588152 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07588152 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07588152 currently recruiting?
Yes, NCT07588152 is actively recruiting participants. Contact the research team at kingbrj@iu.edu for enrollment information.
Where is the NCT07588152 trial being conducted?
This trial is being conducted at Bloomington, United States.
Who is sponsoring the NCT07588152 clinical trial?
NCT07588152 is sponsored by Indiana University. The trial plans to enroll 50 participants.